Grifols (GRFS) Other Non-Current Liabilities (2009 - 2025)
Grifols' (GRFS) quarterly Other Non-Current Liabilities came in at $138.5 million in Q4 2025, up 3.7% YoY from $133.6 million in Q4 2024, and up 3.7% on a QoQ basis from $133.6 million in Q4 2024.
Grifols (GRFS) Other Non-Current Liabilities (2009 - 2025) Analysis & Trends
Grifols (GRFS) has 17 years of Other Non-Current Liabilities data on file, last reported at $138.5 million in Q4 2025.
- Quarterly Other Non-Current Liabilities rose 3.7% year-over-year to $138.5 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $138.5 million (up 3.7% YoY) and the FY2025 annual result came in at $138.5 million, up 3.7% from the prior year.
- Other Non-Current Liabilities improved to $138.5 million in Q4 2025, from $133.6 million in the prior quarter.
- In the past five years, Other Non-Current Liabilities ranged from a high of $138.5 million in Q4 2025 to a low of $17.2 million in Q4 2021.
- A 5-year average of $105.5 million and a median of $125.8 million in 2023 frame the typical range for Other Non-Current Liabilities.
- Annual changes were most pronounced in 2021 — Other Non-Current Liabilities dropped 11.98% — and 2022, when it surged 552.83%.
- Tracing GRFS's Other Non-Current Liabilities over 5 years: stood at $17.2 million in 2021, then soared by 552.83% to $112.3 million in 2022, then advanced by 12.03% to $125.8 million in 2023, then increased by 6.18% to $133.6 million in 2024, then grew by 3.7% to $138.5 million in 2025.
- The last three Other Non-Current Liabilities figures came in at $138.5 million (Q4 2025), $133.6 million (Q4 2024), and $125.8 million (Q4 2023), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Johnson & Johnson | 652.20 Bn | 631.44 Bn | 17.26 Bn |
| 2 | AbbVie | 469.51 Bn | 462.94 Bn | 12.70 Bn |
| 3 | Merck | 376.81 Bn | 369.67 Bn | 12.21 Bn |
| 4 | Novartis Ag | 303.04 Bn | 295.35 Bn | 11.24 Bn |
| 5 | Astrazeneca | 257.61 Bn | 252.71 Bn | 12.86 Bn |
| 6 | Amgen | 237.37 Bn | 223.38 Bn | 7.24 Bn |
| 7 | Gilead Sciences | 181.73 Bn | 178.55 Bn | 6.22 Bn |
| 8 | Pfizer | 159.66 Bn | 147.96 Bn | 10.94 Bn |
| 9 | Gsk | 106.24 Bn | 102.07 Bn | 8.24 Bn |
| 10 | Grifols | 5.45 Bn | 4.45 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 138.52 Mn |
| Dec 31, 2024 | 133.57 Mn |
| Dec 31, 2023 | 125.80 Mn |
| Dec 31, 2022 | 112.29 Mn |
| Dec 31, 2021 | 17.20 Mn |
| Dec 31, 2020 | 19.54 Mn |
| Sep 30, 2020 | 661.48 Mn |
| Mar 31, 2020 | 543.55 Mn |
| Dec 31, 2019 | 8.89 Mn |
| Sep 30, 2019 | 497.08 Mn |
| Dec 31, 2018 | 6.98 Mn |
| Sep 30, 2018 | 500.18 Mn |
| Jun 30, 2018 | 96.90 Mn |
| Mar 31, 2018 | 529.17 Mn |
| Dec 31, 2017 | 6.79 Mn |
| Jun 30, 2017 | 85.29 Mn |
| Dec 31, 2016 | 5.53 Mn |
| Sep 30, 2016 | 97.13 Mn |
| Jun 30, 2016 | 132.34 Mn |
| Dec 31, 2015 | 5.46 Mn |